Περίληψη:
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively as-sessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Bakasis, A.-D.
Bitzogli, K.
Mouziouras, D.
Pouliakis, A.
Roumpoutsou, M.
Goules, A.V.
Androutsakos, T.
Λέξεις-κλειδιά:
angiotensin converting enzyme 2; azathioprine; comirnaty; coronavirus spike glycoprotein; elasomeran; glucocorticoid; immunoglobulin G antibody; messenger RNA; methotrexate; mrna 1273; mycophenolate mofetil; rituximab; SARS-CoV-2 antibody; tumor necrosis factor inhibitor, alcoholic fatty liver; antibody response; Article; autoimmune hepatitis; cardiovascular disease; Child Pugh score; chronic hepatitis B; chronic liver disease; controlled study; coronavirus disease 2019; diabetes mellitus; drug safety; elastography; enzyme linked immunosorbent assay; female; follow up; hepatic sarcoidosis; human; human tissue; humoral immunity; immunosuppressive treatment; interview; kinetics; liver biopsy; liver cirrhosis; liver disease; lung disease; male; Model For End Stage Liver Disease Score; nonalcoholic fatty liver; primary biliary cirrhosis; Severe acute respiratory syndrome coronavirus 2; structured questionnaire; vaccination; virus neutralization
